A wide array of microRNAs (miRNAs) is differentially expressed in breast tumors and also functions as tumor suppressors. Herein, the current study sought to unravel the function of miR-4731-5p in breast cancer progression. First, breast cancer-related miRNA and mRNA microarray data sets were retrieved for differential analyses. Subsequently, the expression patterns of miR-4731-5p, PAICS, and FAK in breast cancer tissues and cells were determined, in addition to analyses of their roles in glycometabolism, migration, invasion, epithelial–mesenchymal transition (EMT) analyzed through functional assays. Next, the targeting relation between miR-4731-5p and PAICS was validated. Xenograft tumors in nude mice were further established to reproduce and verify the in vitro findings. miR-4731-5p was poorly expressed and PAICS was highly expressed in breast cancer tissues and cells. PAICS was confirmed as a target of miR-4731-5p. Moreover, miR-4731-5p exerted an inhibitory effect on glycolysis, EMT, migration, and invasion in breast cancer cells via regulation of PAICS-dependent phosphorylation of FAK. In vivo assay further validated the significance of the miR-4731-5p/PAICS/FAK axis in vivo tumorigenesis and lung metastasis in breast cancer. Collectively, our findings indicated that miR-4731-5p inhibited breast cancer cell glycolysis and EMT through the reduction of PAICS-induced phosphorylation of FAK.

INTRODUCTION

Breast cancer is one of the most common malignancies in the female population, and also represents the leading cause of cancer-related deaths among women [1]. Despite the tremendous advancements in regard to the laboratory, epidemiological and clinical investigations, the morbidity of breast cancer continues to grow [2]. Advanced-stage breast cancer manifests in the form of distant organ metastases, which remain untreatable using currently available strategies [3]. Epithelial–mesenchymal transition (EMT) represents a crucial process in malignancies, wherein epithelial cells transform into a mesenchymal phenotype with enhanced invasive ability to distant sites, thus contributing to tumor progression and metastasis [4]. Meanwhile, the past decade has witnessed a surge of microRNAs (miRNAs) in crucial processes such as tumorigenesis and tumor metastasis, with certain miRNAs implicated in the regulation of tumor invasion/metastasis via EMT- and/or non-EMT-dependent mechanisms [5]. In lieu of the same, it would be practical to investigate the miRNA-mediated EMT mechanism in regard to breast cancer to aid the development of therapeutic targets against the lethal malignancy.

Inherently, miRNAs are defined as short, non-coding RNAs, which possess the ability to repress the translation of target messenger RNA (mRNAs) and induce their degradation [6]. One such miRNA, miR-4731-5p (miR-4731) is regarded as a melanoma-enriched miRNA, whereas its deficiency is known to contribute to the progression of advanced melanomas [7]. Interestingly, miR-4731-5p has been previously highlighted as a tumor-suppressor in glioma [8], especially in glioblastoma multiforme [9]. Meanwhile, the PAICS gene was recently indicated as a tumor-promotive gene in several human cancers including lung adenocarcinoma (LADC) [10], cervical cancer [11], and even breast cancer [12]. Moreover, PAICS is capable of allosterically-activating pyruvate kinase M2 (PKM2), which directly binds to integrin β1 and consequently activates focal adhesion kinase (FAK) [13, 14]. The latter is noteworthy as FAK is established as a crucial inducer of growth factors and anchorages, and also a promoter of glycolysis through upregulation of pivotal glycolytic proteins, such as enolase and PKM2 [15]. Interestingly, a prior study unveiled that the loss of FAK in cancer-associated fibroblasts (CAFs) could enhance chemokine production, and subsequently promote malignant cell glycolysis [16]. In addition, FAK activation underlies IGF1R-dependent EMT, migration, and invasion in triple-negative breast cancer [17]. As PAICS was highlighted as a potential target gene of miR-4731-5p by initial bioinformatics analysis in our investigation, we speculated that miR-4731-5p might regulate the oncogene PAICS to modulate FAK-driven glycolysis and EMT in breast cancer. Accordingly, we carried out a series of cellular and animal experiments to testify this hypothesis, in an effort to broaden our understanding of breast cancer progression.
RESULTS
miR-4731-5p and PAICS are predicted to be involved in breast cancer

Initial analyses of the GSE57897 microarray data set indicated a reduction in miR-4731-5p expression in breast cancer samples (Fig. 1A), however, there is no relevant research in regard to the role of miR-4731-5p in breast cancer. In order to further elucidate the mechanism of miR-4731-5p in breast cancer, the target genes of miR-4731-5p were predicted using the starBase and TargetScan databases. Additionally, the significantly highly expressed genes in TCGA breast cancer were retrieved from the GEPIA2 database. In addition, 662 significantly highly expressed genes were obtained from the microarray data set GSE3744 (Fig. 1B). Subsequently, the predicted target genes from starBase and TargetScan, highly expressed genes in TCGA, and highly expressed genes from the GSE3744 data set were intersected, obtaining a total of 19 intersected genes (Fig. 1C). Further interaction analyses of these 19 genes were carried out, and their related genes were amplified at the same time to obtain the interaction score, with PAICS exhibiting the highest score in the interaction network (Fig. 1D and Supplementary Table 2).

Further quantitative analysis of the top 10 genes (namely, SBK1, CTXN1, SAPCD2, VANG1, PLEK2, SPC24, PRR11, PAQR4, PAICS, and PITX1) with the highest interaction scores validated that the difference in PAICS expression was the most pronounced (Supplementary Fig. 1). Moreover, PAICS was also significantly highly expressed in breast cancer tissue samples included in the TCGA and GTEx databases (Fig. 1E). Meanwhile, existing evidence indicates that PAICS possesses the ability to regulate the progress of glycolysis by regulating the phosphorylation of FAK [14]. Altogether, these findings highlight the involvement of miR-4731-5p and PAICS in breast cancer.

miR-4731-5p suppresses glycolysis, EMT, migration, and invasion of breast cancer cells

miR-4731-5p has been previously shown to suppress tumor metastasis in malignant tumors, but its role in breast cancer remains elusive [8]. The results of RT-PCR demonstrated that miR-4731-5p expression levels were diminished in breast cancer tissues (Fig. 2A and Supplementary Fig. 2A), as well as in breast cancer cells MDA-MB-453, MCF-7, and MDA-MB-231. The MCF-7 and MDA-MB-231 cell lines exhibited the least reduced miR-4731-5p expression of all the samples tested (Fig. 2A and Supplementary Fig. 2A).
expressions among the four cell lines and thus were selected for further in vitro cell experiments (Fig. 2B and Supplementary Fig. 2B).

Subsequent results from RT-qPCR also illustrated that miR-4731-5p mimic treatment brought about increased miR-4731-5p expression levels (Fig. 2C, Supplementary Fig. 3A). In addition, miR-4731-5p mimic treatment reduced the glycolysis rate, glucose consumption, and lactic acid content (Fig. 2D, E and Supplementary Fig. 3B, C). Moreover, increased miR-4731-5p led to reduced expressions of glycolysis-related genes PKM2, GLUT1, and mesenchymal marker Vimentin, while increasing those of the epithelial-related marker E-Cadherin (Fig. 2F and Supplementary Fig. 3D). Western blot assay results were in line with those of RT-qPCR (Fig. 2G and Supplementary Fig. 3E). Immunofluorescence results demonstrated the presence of upregulated E-Cadherin, and downregulated Vimentin expressions after miR-4731-5p mimic treatment, indicating that miR-4731-5p could inhibit EMT of tumor cells (Fig. 2H and Supplementary Fig. 3F). Moreover, the cell migration and invasion abilities were found to be inhibited after overexpression of miR-4731-5p (Fig. 2I, J and Supplementary Fig. 3G, H).

Thereafter, we transfected negative control (NC) inhibitor or miR-4731-5p inhibitor into normal breast cell line MCF10A, and decreased miR-4731-5p expression levels were documented in response to miR-4731-5p inhibition (Supplementary Fig. 4A), while there were no significant differences in comparison of the above two groups in other experiments (Supplementary Fig. 4B–I), which underscored the specific effect of miR-4731-5p overexpression on glycolysis, EMT, migration, and invasion of breast cancer cells.

**miR-4731-5p targets PAICS**

PAICS was previously reported to promote the malignant progression of breast cancer [18]. Herein, the results of RT-PCR and western blot assay illustrated that PAICS expression levels
were enhanced in breast cancer tissues (Fig. 3A, B). Similar elevations in PAICS expressions were observed in breast cancer cells, wherein MCF-7 and MDA-MB-231 cells exhibited the most profound upregulation, and thus were selected for further experimentation (Fig. 3C).

Subsequent in silico analysis predicted the presence of a binding site between miR-4731-5p and PAICS, which was further validated by the results of the luciferase assay (Fig. 3D). Moreover, there was a reduction in PAICS expression upon miR-4731-5p mimic treatment, while the opposing trends were documented following miR-4731-5p inhibition (Fig. 3E, F and Supplementary Fig. 5A, B). Together, the aforementioned findings indicated that miR-4731-5p could target PAICS.

PAICS induces phosphorylation of FAK in breast cancer

Existing evidence suggests that PAICS can regulate the activity of pyruvate kinase and regulate the activity of PKM2, whereas PKM2 is regarded as a critical regulatory molecule in the glycolysis process, and can also promote the glycolysis process by phosphorylating FAK [13, 14]. Accordingly, we explored the regulatory relationship between PAICS and FAK, and uncovered that there were no significant differences in FAK expressions between breast cancer tissues and adjacent tissues (Fig. 4A, B). Moreover, we observed the same results in breast cancer cells relative to mammary epithelial cells (Fig. 4C).

Subsequent experimentation revealed that miR-4731-5p mimic/inhibitor exerted no effect on the expression of FAK (Fig. 4D, E and Supplementary Fig. 6A, B), whereas PAICS overexpression elevated PAICS expression levels, but did not influence FAK expression (Fig. 4F and Supplementary Fig. 6C). The results of Western blot analysis further illustrated that oe-PAICS treatment elevated PAICS and p-FAK expression, but exerted no influence on FAK expression levels (Fig. 4G and Supplementary Fig. 6D). Overall, these findings indicated PAICS could promote FAK phosphorylation in breast cancer cells.

Downregulation of FAK inhibits glycolysis, EMT, migration, and invasion of breast cancer cells

To further elaborate on the role of PAICS in breast cancer, we first established a PAICS silencing cell line. RT-PCR results illustrated that PAICS siRNA-3 exhibited the most pronounced silencing efficiency, and thus was selected for further experiments (Fig. 5A, Supplementary Fig. 7A). Subsequent experimentation illustrated that downregulation of PAICS led to a reduction in PKM2, GLUT1, Vimentin, N-cadherin, Zeb1, Snail, and Slug levels, while elevating those of E-cadherin (Fig. 5B, C and Supplementary Fig. 7B, C). Moreover, p-FAK expression levels were significantly reduced following downregulation of PAICS (Fig. 5I and Supplementary Fig. 7I).

Downregulation of PAICS further contributed to reductions in the glycolysis rate, glucose consumption, and lactic acid content (Fig. 5D, E and Supplementary Fig. 7D, E). Moreover, downregulation of PAICS brought about inhibited EMT in breast cancer (Fig. 5F and Supplementary Fig. 7F). In addition, repressed cell migration and invasion abilities were documented following downregulation of PAICS (Fig. 5G, H and Supplementary Fig. 7G, H). Altogether, these findings indicated that downregulation of FAK could inhibit glycolysis, EMT, migration, and invasion of breast cancer cells.
PAICS reverses the suppressive role of miR-4731-5p in glycolysis, EMT, migration, and invasion of breast cancer cells

Furthermore, we validated the underlying mechanism of the miR-4731-5p/PAICS/p-FAK axis in breast cancer. The results of RT-qPCR illustrated that individual oe-PAICS treatment led to increased PAICS expression levels, while further miR-4731-5p mimic increased the miR-4731-5p expression and reduced PAICS levels (Fig. 6A, B and Supplementary Fig. 8A, B). Besides, overexpression of PAICS gave rise to increased PAICS, PKM2, GLUT1, Vimentin, N-cadherin, Zeb1, Snail, and Slug expression levels, and decreased E-cadherin expression, whereas the addition of over-expressed miR-4731-5p reversed the aforementioned trends (Fig. 6B, C and Supplementary Fig. 8B, C). Moreover, there was a significant increase in the expression of p-FAK after individual oe-PAICS treatment, while being reduced following miR-4731-5p mimic treatment (Fig. 6D and Supplementary Fig. 8D).

Subsequent results of glycolysis experimentation illustrated that oe-PAICS treatment brought about a significant increase in the glycolysis rate, glucose consumption, and lactic acid production, while these promotions were inhibited by miR-4731-5p mimic treatment (Fig. 6D, E and Supplementary Fig. 8D, E). Immunofluorescence results further demonstrated that oe-PAICS induced the EMT of tumor cells, while miR-4731-5p mimic countered this effect (Fig. 6F and Supplementary Fig. 8F). Additionally, overexpression of PAICS led to an enhancement in the migration and invasion of breast cancer cells, whereas miR-4731-5p mimic treatment led to the opposing trends (Fig. 6G, H and Supplementary Fig. 8G, H). Altogether, these findings indicated that PAICS could reverse the suppressive role of miR-4731-5p in glycolysis, EMT, migration, and invasion of breast cancer cells.

miR-4731-5p represses in vivo tumorigenesis and metastasis in breast cancer through PAICS/p-FAK

To further validate the effects of the miR-4731-5p/PAICS/p-FAK axis on breast cancer in vivo, we established a nude mouse model of breast cancer xenograft tumor. There was an increase in tumor volume and weight following PAICS overexpression, while additional treatment with miR-4731-5p agomir reversed these trends (Fig. 7A–C). Moreover, miR-4731-5p expression levels were increased by the injection of miR-4731-5p agomir in the presence of oe-PAICS (Fig. 7D). Meanwhile, overexpression of PAICS augmented the expressions of PAICS, p-FAK, Vimentin, N-cadherin, Zeb1, Snail, and Slug, and reduced that of E-Cadherin in the tumors, whereas additional treatment with miR-4731-5p agomir reversed the aforementioned trends (Fig. 7E). In addition, oe-PAICS treatment gave rise to elevated expressions of glucose metabolism-related protein GLUT1 in tumor tissues, while further miR-4731-5p agomir treatment countered the said effect on GLUT1 expression (Fig. 7F).

Furthermore, we established breast cancer lung metastasis models and counted the metastatic tumor nodules 5 weeks later, and found that oe-PAICS treatment increased lung tumor metastases, whereas further miR-4731-5p agomir treatment decreased lung tumor metastases in nude mice (Fig. 7G). The results of Hematoxylin and Eosin staining further illustrated that lung metastases showed typical adenocarcinoma nests in nude mice after oe-PAICS treatment (Fig. 7H). As evidenced by immunohistochemistry results, overexpression of PAICS gave rise to increased expressions of p-FAK and PAICS, while additional treatment with miR-4731-5p agomir reversed the trends (Fig. 7I). We also documented similar expression trends concerning the expression of p-FAK and PAICS in the breast cancer lung metastasis model as in the nude mouse model of breast cancer xenograft tumor by immunohistochemistry (Supplementary Fig. 9). Altogether, the aforementioned findings indicated that miR-4731-5p could repress in vivo tumorigenesis and metastasis in breast cancer through PAICS/p-FAK.

DISCUSSION

The current study set out to unravel the function of miR-4731-5p in breast cancer progression, and the obtained findings highlighted the antitumor activity of miR-4731-5p in breast cancer through suppression of glycolysis and reversal of EMT. In addition, we also uncovered a regulatory axis, wherein miR-4731-5p targeted PAICS and consequently inhibited phosphorylation of FAK which impeded glycolysis and blocked the EMT process (Fig. 8).

Initial findings in our study revealed that miR-4731-5p was poorly expressed in breast cancer, whereas its re-expression
exerted a diminishing effect on the glycolysis of breast cancer cells and their migration and invasive abilities. Despite the lack of research in regard to the role of miR-4731-5p in breast cancer, the hard-done work of our peers has shed light on the tumor-suppressive role of miRNAs in various malignancies, including stage IV melanoma [7], and glioblastoma [9]. More importantly, downregulation of miR-4731-5p, the focus of our study, was previously detected in oral squamous cell carcinoma, and further correlated with malignant transformation of oral lichen planus as well as malignant characteristics [19].

Further experimentation in our study established that the PAICS oncogene served as a target gene of miR-4731-5p. Moreover, PAICS knockdown led to suppression of glycolysis, EMT, migration, and invasion in breast cancer cells, similar to the effects precipitated by re-expression of miR-4731-5p. In line with our results, Meng et al. previously indicated that downregulation of PAICS could prevent the malignant progression of breast cancer [12]. Furthermore, a number of prior studies have elaborated on the role of PAICS in several cancers. For instance, depletion of PAICS suppressed the proliferative and invasive abilities of pancreatic ductal adenocarcinoma cells [20].

On the other hand, PAICS, activated in LADC tissues, was previously shown to function as a tumor-promoting gene [10]. Meanwhile, loss of PAICS can not only impede the growth of gastric cancer cells but also induces their apoptosis and DNA damage [21]. Further in line with our findings, PAICS is capable of reversing the blockade of EMT triggered by miR-504 [11]. The latter is particularly noteworthy as EMT programs are

Fig. 5 Decreased PAICS inhibits the glycolysis, EMT, migration, and invasion of MCF-7 cells. A RT-qPCR was used to detect the expression of PAICS in breast cancer cells. B RT-qPCR was used to detect the expression of PAICS, FAK, PKM2, GLUT1, Vimentin, N-cadherin, Zeb1, Snail and Slug, and E-Cadherin. C Western blot analysis was used to detect the expression of PAICS, FAK, PKM2, GLUT1, Vimentin, N-cadherin, Zeb1, Snail and Slug, and E-Cadherin. D The effect of PAICS on glycolysis of breast cancer cells. E The effect of PAICS on glucose and lactic acid content of breast cancer cells. F Immunofluorescence was used to detect the expression of EMT-related markers Vimentin and E-Cadherin, scale bar = 25 μm. G Detection of cell migration by scratch test after PAICS siRNA treatment. H Detection of cell invasion by transwell assay after PAICS siRNA treatment. I Western blot analysis was used to detect the expression of p-FAK after PAICS siRNA treatment. Measurement data were expressed as mean ± standard deviation. Comparison between two groups was performed through an independent t test. Analysis among multiple groups was conducted by one-way ANOVA followed by Tukey’s post hoc test. *p < 0.05 compared with siRNA-NC treatment.
essential for the facilitation of breast cancer invasion, and micrometastases are also partially-dependent on FAK [25]. FAK also possesses the ability to induce EMT and cisplatin resistance in breast cancer cells [26]. Meanwhile, the FAK enzymatic activity was previously attributed to β3 integrin-induced fibroblast growth factor receptor (FGFR) signaling that physically disrupts the interaction between FGFR1 and E-cadherin, paving the way for metastatic outgrowth [27]. Further, in accordance with our findings, a prior study documented that inactivation of the αβ3 integrin/FAK/PI3K/Akt pathway served as a critical mechanism for effective blockade of EMT by oxymatrine in breast cancer cells [28]. In addition, activated SRC after phosphorylation at Y418 and FAK phosphorylation at Y861 and Y925 of SRC substrate sites, were previously illustrated to be closely associated with the EMT phenotype [29]. Besides, another study established that leptin elevates the expression levels of Twist and β-catenin, as well as the release of invasion markers MMP-2 and MMP-9 in breast cancer cells, leading to enhanced cell invasion in an SRC- and FAK-dependent way [30]. Interestingly, blocking the SRC/EGFR-dependent ITGB4/FAK pathway, which subsequently inactivates the Akt and p38/MAPK pathways contributes to the suppression of migration and invasiveness of breast cancer cells and reversal of EMT process after treatment with Ziyu II [31]. Herein, we unfolded that overexpression of PAICS could promote cell glycolysis and induced EMT by phosphorylating FAK, which could potentially serve as the mechanism contributing to breast cancer progression due to loss of miR-4731-5p.

Collectively, our findings highlighted the tumor-suppressive and anti-metastatic roles of miR-4731-5p in breast cancer. In addition, we proposed a mechanism wherein miR-4731-5p represses PAICS-dependent phosphorylation of FAK, whereby suppressing the glycolysis of breast cancer cells and reversing EMT process. Although we successfully substantiated the tumor-suppressive and anti-metastatic functions of miR-4731-5p agomir in nude mouse models, it would be prudent to carry out further clinical trials with large sample sizes before therapeutic use.

**METHODS**

**Ethics statement**

All research protocols were approved by Chongqing University Central Hospital and in accordance with the Declaration of Helsinki. Signed informed consents were obtained from all participants prior to specimen collection.
miR-4731-5p inhibits in vivo tumorigenesis and metastasis in breast cancer through PAICS/p-FAK. A The volume of tumor in nude mice was statistically analyzed. B Representative images of xenograft tumors. C Tumor weight in mice after oe-PAICS and miR-4731-5p agomir treatment. D RT-qPCR was used to detect the expression of miR-4731-5p in tumors after oe-PAICS and miR-4731-5p agomir treatment. E RT-qPCR was used to detect the expression of PAICS, p-FAK, Vimentin, N-cadherin, Zeb1, Snail, Slug, and E-Cadherin. F Western blot analysis was used to detect the expression of GLUT1 in tumors. G The lung and lung tumor metastases in mouse models were observed (the arrow indicates the number of lung metastases). H H&E staining was used to observe the metastasis of lung tissue, scale bar = 25 μm. I The expression of p-FAK and PAICS in nude mice was detected by immunohistochemistry. Measurement data were expressed as mean ± standard deviation. Analysis among multiple groups was conducted by one-way ANOVA followed by Tukey’s post hoc test, n = 10. * p < 0.05 compared with oe-NC + agomir NC treatment. ** p < 0.05 compared with oe-PAICS + agomir NC treatment.
Following a 24-h period of regular culture, the cells were transfected upon inoculation in a six-well plate, at a density of 1 × 10^5 cells per well. The obtained breast cancer cell lines (namely, MDA-MB-436, MDA-MB-453, MCF-7, and MDA-MB-231) were all purchased from ATCC (Manassas, VA). The obtained breast cancer-related miRNA microarray data set GSE57897 (comprising of 31 normal samples and 422 breast cancer samples) and miRNA microarray data set GSE3744 (comprising of seven normal samples and 40 breast cancer samples) were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes \((|\log FC| > 0.8, \text{adj. } p \text{ value} < 0.05)\) were identified using the R language “limma” package, with normal samples as controls. The different \(p\) values were corrected with the false discovery rate method. The false-positive rate was decreased by adjusted \(p\) values using the Benjamini and Hochberg false discovery rate method by default. Additionally, the target genes of miR-4731-5p were obtained from the starBase and TargetScan databases. Furthermore, the differentially expressed genes in the TCGA and GTEx databases were downloaded using the GEPIA server. Thereafter, an interaction analysis was performed on the candidate target genes with the interaction scores obtained with the help of the GeneMANIA database.

**Sample collection**
A total of 50 patients who underwent breast tumor resection at the Chongqing University Central Hospital from January 2017 to December 2020, were enrolled in the current study to obtain breast cancer tissues and adjacent normal tissues. The included patients had an age range of 37–72 years, with a mean calculated age of \((57.68 ± 7.30)\) years. None of the included patients had received antitumor therapy prior to specimen collection and were considered as breast cancer by means of postoperative pathological biopsy.

**Cell culture and transfection**
Breast cancer cell lines (namely, MDA-MB-436, MDA-MB-453, MCF-7, and MDA-MB-231) were all purchased from ATCC (Manassas, VA). The obtained cells were cultured in RPMI-1640 (Gibco, USA) containing 10% fetal bovine serum (FBS, Gibco), 100 µg/mL streptomycin, and 100 U/mL penicillin, and placed in a humidified incubator at 37°C with 5% CO\(_2\) in air (Thermo Fisher, Waltham, MA). Cells at the logarithmic phase were trypsinized and inoculated in a six-well plate, at a density of \(1 \times 10^3\) cells per well. Following a 24-h period of regular culture, the cells were transfected upon reaching 75% confluence. The concentration of NC, miRNA mimic, or miRNA inhibitor was set as 50 nM (RiboBio Biotechnology Co., Ltd., Guangzhou, China). Transfection was carried out using the Lipofectamine 3000 (L3000001, Thermo Fisher) reagent.

**Western blot analysis**
Western blot analysis was carried out with following primary rabbit antibodies: PKM2 (ab137852, 1:1000), GLUT1 (ab115730, 1:1000), PAICS (ab229531, 1:1000), FAK (ab40794, 1:1000), p-FAK (ab81298, 1:1000), Snail (ab216347, 1:1000), Slug (ab27568, 1:1000), N-cadherin (ab76011, 1:1000), Zeb1 (ab203829, 1:1000), E-cadherin (ab40772, 1:1000), Vimentin (ab92547, 1:1000), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; ab8227, 1:1000), and the production antibody horseradish peroxidase-labeled goat anti-rabbit immunoglobulin (ab205718, 1: 20000). The protein quantitative analysis was performed with the gray value of each protein and the gray ratio of the internal reference GAPDH using the ImageJ software. All the aforementioned antibodies were purchased from Abcam (Cambridge, UK).

**Glycolysis assay**
The degree of glycolysis in breast cancer cells under different conditions was detected by means of a glycolysis assay (ab197244, Abcam). Meanwhile, the degree of glucose consumption in breast cancer cells was measured using the micro method (BC2505, Solarbio). Briefly, the collected cells were centrifuged with the supernatant removed. According to the ratio of \(500:1–10000\) of the number of cells (10,000 cells): volume of distiller water (mL), the cells were broken by ultra-sonification (ice bath, power 20% or 200 W, ultrasonic 3 s, 10 s interval, repeated for 30 times) and then water-bathed at 95°C for 10 min (cover tightly to prevent water loss). After being allowed to cool down, the cells were centrifuged at 8000 × g at 25°C for 10 min, with the supernatant collected for later use. A spectrophotometer/plate reader was subsequently warmed up for >30 min, with the wavelength adjusted to 505 nm for detection purposes. Additionally, the micro method was applied another time for detection of the degree of lactic acid production (BC2235, Solarbio), and the procedures were the same as those for glucose detection. The spectrophotometer/plate reader was warmed up for more than 30 min, with the wavelength adjusted to 570 nm for detection purposes.

**Scratch test**
After detachment, cells were seeded in a 24-well plate, and upon reaching 90% cell confluence, scratches were made using a sterile pipette tip. After a phosphate-buffered saline (PBS) rinse, the corresponding treatment was performed. Followed a 48-h treatment period, images were obtained. The ImageJ software was adopted to calculate the scratch area.

**Transwell assay**
Breast cancer cells were cultured in a serum-free medium for 12 h, harvested, and resuspended in a serum-free medium \((1 \times 10^6)/mL\). The lower chamber was added with 10% FBS, and 100 µL of cell suspension was added to the Transwell chamber (PIEP12R48, Millipore, Darmstadt, Germany) coated with Matrigel (356231, Corning BioCoat, Bedford). Following a 24-h incubation period at 37°C, the cells that did not invade the cell surface were gently removed with cotton swabs. The remaining cells were then fixed with 100% methanol and stained with 20% crystal violet (Sigma). The stained invaded cells were counted manually under five randomly selected areas using an inverted optical microscope (CarlZeiss, Jena, Germany), and each experiment was repeated three times to obtain the mean value. The procedure of the migration experiment was the same without Matrigel.

**Dual-luciferase reporter gene assay**
The TargetScan webserver was adopted to predict the targeted binding site. The artificially-synthesized WT and MUT of the PAICS 3′-UTR region transcription kits (D1801, Harbin Xinhai Genetic Testing Co., Ltd., Harbin, China) were utilized with miRNA fluorescence quantitative PCR (AQ101-02, Quanshijin, Beijing). Meanwhile, for miRNA detection, RNA reverse transcription kits (KR116, Tiangen Biotechnology Co., Ltd., Beijing, China) were adopted with a fluorescent quantitative PCR instrument Applied Biosystems Viia™7 (LifeTechnologies, Inc., Applied Biosystems, Foster City, CA). Transcriptional levels of the genes were calculated using the \(2^{-\Delta \Delta Ct}\) quantification method, with \(\beta\)-actin and U6 serving as internal references. The absolute copy number of each miRNA was determined with a standard curve. To this end, miRNA oligonucleotides (IDT, Iowa, Coralville) were utilized to produce standard curves at various concentrations \((1 \times 10^{-6} \text{molecules/reaction})\). The sequence of mature miRNA was CCUAAUUUGAACACCUUCGGUA.
were inserted into the luciferase reporter vector pmiR-RB-Report™ (Cat. No.: E1330, Promega, Madison, WI). Subsequently, the 3'-UTR luciferase vector (150 ng) and miR-4731-5p mimic (50 nmol/L) or NC were co-transfected into breast cancer cells using the Lipo 2000 reagent (Invitrogen, Carlsbad, CA). The luciferase activity was detected using luciferase detection kits (Promega) and a GloMax20/20 luminometer (Promega).

**Immunofluorescence**

Following cell-processing, the medium was removed at the corresponding time points, and the cells were rinsed with PBS thrice, fixed with 4% paraformaldehyde for 15 min. and then stored at 4°C for short-term storage. Subsequently, the cells were rinsed thrice with a PBS solution containing 0.1% Tween-20. PBS solution containing 0.25% Triton X-100 (PBST) at room temperature for 10 min, and PBST solution containing 1% BSA + 22.52 mg/ml Glycine + 0.1% Tween-20 for 30 min at room temperature. Next, the cells were incubated with the following corresponding primary antibodies: rabbit anti-E-cadherin (ab40772, 1:100, Abcam) and rabbit anti-Vimentin (ab92547, 1:100, Abcam) at 4°C overnight. The following day, the cells were rinsed thrice with PBST solution and incubated with the corresponding fluorescent secondary antibody at room temperature for 1 h. Afterward, the cells were stained with 1 μg/mL DAPI at room temperature for 5 min, rinsed thrice with PBST solution, followed by observation and photography with a fluorescence microscope.

**Immunohistochemistry**

Paraaffin-embedded sections were fixed with formalin and sectioned (thickness of 4 μm), dewaxed in xylene, and rehydrated. Enzymatic peroxidase activity was quenched with the addition of 3% hydrogen peroxide dissolved in methanol for 10 min, and the sections were subjected to antigen repair for 15 min. Next, the sections were blocked for 20 min with normal rabbit serum and incubated with anti-p-FAK (Abcam) and anti-PAICS (Abcam) overnight at 4°C. The following day, the sections were incubated with the secondary antibody for 30 min, and stained with streptavidin peroxidase detection system, counterstained with hematoxylin with diamobenzidazone as a chromogenic agent. PBS was adopted as the NC.

**Xenograft tumor in nude mice**

A total of 60 healthy female nude mice (aged 4–6 weeks old, procured from Shanghai SLAC Laboratory Animal Co., Ltd) were raised in an SPF animal laboratory in single cages under controlled conditions (laboratory from Shanghai SLAC Laboratory Animal Co., Ltd) were raised in an SPF room temperature for 5 min, and then stored at 4°C for short-term storage. All mice had ad libitum access to food and water and were raised under 12 h light and dark cycles. The animal laboratory in single cages under controlled conditions (laboratory from Shanghai SLAC Laboratory Animal Co., Ltd) were raised in an SPF

**Data Availability**

The data that support the findings of this study are available on request from the corresponding author upon reasonable request.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20:417–36.
3. Harbeck N, Penault-Llorca F, Cortes J, Grant M, Housami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.
4. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol. Oncol. 2011;7:11–28.
5. Ding XM. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer. 2014;33:140–7.
6. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.
7. Stark MS, Tom LN, Boyle GM, Bonazzi VF, Soyer HP, Herington AC, et al. The “malignoma-enriched” microRNA miR-4731-5p acts as a tumour suppressor. Oncotarget. 2016;7:9677–87.
8. Yan Z, Zhang W, Xiong Y, Wang Y, Li Z. Long noncoding RNA FLYCR1-AS1 aggravates biological behaviors of glioma cells via targeting miR-4731-5p/EF2 axis. Biochem Biophys Res Commun. 2020;521:716–20.
9. Allahverdi A, Arefian E, Soleimani M, Ai J, Nahamoghadam N, Yousefi-Ahmadipour A, et al. MicroRNA-4731-5p delivered by AD-mesenchymal stem cells induces cell cycle arrest and apoptosis in glioblastoma. J Cell Physiol. 2020;235:8167–75.
10. Zhou S, Yan Y, Chen X, Wang X, Zeng S, Qian L, et al. Roles of highly expressed PAICS in lung adenocarcinoma. Gene. 2019;692:1–8.
11. Ou ZY, Cui GY, Shi PJ, Wang HQ. Potential suppressive functions of microRNA-504 in cervical cancer cells malignant process were achieved by targeting PAICS and regulating EMT. Arch Gynecol Obstet. 2020;302:173–82.
12. Meng M, Chen Y, Jia J, Li L, Yang S. Knockdown of PAICS inhibits malignant proliferation of human breast cancer cell lines. Biol Res. 2018;51:24.
13. Goswami MT, Chen G, Chakravarthi BV, Pathi SS, Anand SK, Caskadon SL, et al. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015;6:3445–61.
14. Wang C, Zhang S, Liu J, Tian Y, Ma B, Xu S, et al. Secreted pyruvate kinase M2 promotes lung cancer metastasis through activating the integrin beta1/FAK signaling pathway. Cell Rep. 2020;30:1780–97 e1786.
15. Zhang J, Gao Q, Zhou Y, Dier U, Hempel N, Hochwald SN. Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis. Oncogene. 2016;35:1926–42.
16. Demircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, et al. Cancer associated fibroblast FAK regulates malignant cell metabolism. Nat Commun. 2020;11:1290.
17. Tallaferro-Smith L, Oberlick B, Liu T, McGlothlen T, Alicade T, Tobin R, et al. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget. 2015;6:4757–72.
18. Gallenne T, Ross KN, Visser NL, Salomy, Desmet CJ, Wittner BS, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8:20572–87.
19. Gholizadeh N, Emami Razavi A, Mohammadpour H, Tavakol F, Shelykhbabaei N, Association of MAPK and PI3K regulatory miRNAs, 6003, 4301, 8485, and 4731 with the malignant transformation of oral lichen planus. Mol Biol Rep. 2020;47:1223–32.
20. Agarwal S, Chakravarthi B, Kim HG, Gupta N, Hale K, Babalosubramanya SAH, et al. PAICS, a de novo purine biosynthetic enzyme, is overexpressed in pancreatic cancer and is involved in its progression. Transl Oncol. 2020;13:100776.
21. Huang N, Xu C, Deng L, Li X, Bian Z, Zhang Y, et al. PAICS contributes to gastric carcinogenesis, and participates in DNA damage response by interacting with histone deacetylase 1/2. Cell Death Dis. 2020;11:507.
22. Benzina S, Harquail J, Guerrette R, O'Brien P, Jean S, Crapoulet N, et al. Breast cancer malignant processes are regulated by Pax-5 through the disruption of FAK signaling pathways. J Cancer. 2016;7:2035–44.
23. Qin X, Lin L, Cao L, Zhang X, Song X, Hao J, et al. Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycosylation. Sci Rep. 2017;7:45305.
24. Zhou J, Zhu J, Jiang G, Feng J, Wang Q. Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK. Onco Targets Ther. 2019;12:4595–604.
25. Wendt MK, Schiemann BJ, Parvanji JG, Lee YH, Kang Y, Schiemann WP. TGFB-beta stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene. 2013;32:2005–15.
26. Luo J, Yao JF, Deng XF, Zheng XD, Jia M, Wang YQ, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin alphavbeta3 and activating FAK/PISK/akt signaling. J Exp Clin Cancer Res. 2018;37:23.
This work was supported by the Natural Science Foundation of CQCSTC (grant no. cstc2020jcyj-msxmX0845) and the Basic Research and Frontier Exploration Project of Chongqing Yuzhong District (grant no.20200138) to Lei Lang; and supported by Chongqing Young and Middle-aged Medical Professionals Cultivation Program (grant no.2019JCYJXQ003) and Chongqing Science and Health Joint Medical Research Project (grant no. 2019ZDXM028) to Wei Li.

AUTHOR CONTRIBUTIONS
L.L.: conceptualization; data curation; writing-original draft. J.T.: formal analysis; investigation; supervision. C.Y.: methodology; resources; software; project administration. W.L.: funding acquisition; writing-review & editing.

COMPETING INTERESTS
The authors declare no competing interests.